PACAP Receptor Inhibitors

PACAP receptor inhibitors are chemicals designed to modulate the activity of the PACAP receptors, which include PAC1, VPAC1, and VPAC2 receptors. These receptors are crucial in mediating various physiological responses to the neuropeptide PACAP, such as neurodevelopment, neuroprotection, stress response, and regulation of circadian rhythms. The inhibitors listed above target these receptors by either competing with PACAP for binding or interfering with receptor activation, leading to a decrease in PACAP-mediated signaling. The PAC1 receptor is primarily targeted by peptide antagonists such as PACAP(6-38), SNAP 37889, Maxadilan, [Ac-His^1, D-Phe^2, D-Trp^3,6]-PACAP-(1-27), and PACAP(6-27). These compounds mimic or modify portions of the PACAP molecule, competitively inhibiting its binding to the PAC1 receptor. This inhibition results in reduced biological responses typically mediated by the activation of the PAC1 receptor, such as neuronal survival, synaptic plasticity, and stress responses.

In contrast, VPAC1 and VPAC2 receptors, which also respond to VIP (Vasoactive Intestinal Peptide) in addition to PACAP, are targeted by inhibitors like M65, PG 99-465, Ro 25-1553, VIP(6-28), PG 97-269, BIM 23056, and [N-Ac-Tyr^1, D-Phe^2]-GRF(1-29)-NH2. These inhibitors specifically block the binding of PACAP and VIP to VPAC1 and VPAC2 receptors. By doing so, they modulate a variety of physiological processes, including smooth muscle relaxation, glycogenolysis, and vasodilation, which are typically induced upon receptor activation. The development and use of these inhibitors are significant in the study of PACAP's role in physiological and pathological processes. By selectively blocking PACAP receptor subtypes, researchers can dissect the specific functions of each receptor, contributing to a better understanding of the biological roles of PACAP.